BeiGene at EHA2024

As a global oncology company, we understand the importance of convening the best researchers to tackle today’s toughest cancer challenges. This is why BeiGene is once again joining experts from around the world at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain. During the meeting, we’ll share our latest research across our hematology portfolio and pipeline. Learn more about all we have planned.

BeiGene will share 28 abstracts at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024, with four scheduled for oral presentations featuring both approved products and pipeline.

BeiGene’s Chief Medical Officer for Hematology shares his thoughts on what makes BeiGene’s science so unique.

At BeiGene, we believe in the power of storytelling. Each of us has our own lived experience and unique perspectives that we can honor and learn from—whether we are a patient, scientist, care partner, or advocate. Our voices individualize us. Together, our diverse voices unite and empower us against cancer. Hear the voices and stories that inspire us against cancer.